Literature DB >> 27631774

Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Georgios Gemenetzis1, Fabio Bagante, James F Griffin, Neda Rezaee, Ammar A Javed, Lindsey L Manos, Anne M Lennon, Laura D Wood, Ralph H Hruban, Lei Zheng, Atif Zaheer, Elliot K Fishman, Nita Ahuja, John L Cameron, Matthew J Weiss, Jin He, Christopher L Wolfgang.   

Abstract

OBJECTIVE: To evaluate the correlation between neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values, and the presence of invasive carcinoma in patients with intraductal papillary mucinous neoplasm (IPMN).
BACKGROUND: NLR and (PLR) are inflammatory markers that have been associated with overall survival in patients with invasive malignancies, including pancreatic cancer.
METHODS: We retrospectively reviewed 272 patients who underwent surgical resection for histologically confirmed IPMN from January 1997 to July 2015. NLR and PLR were calculated and coevaluated with additional demographic, clinical, and imaging data for possible correlation with IPMN-associated carcinoma in the form of a predictive nomogram.
RESULTS: NLR and PLR were significantly elevated in patients with IPMN-associated invasive carcinoma (P < 0.001). In the multivariate analysis, NLR value higher than 4 (P < 0.001), IPMN cyst of size more than 3 cm (P < 0.001), presence of enhanced solid component (P = 0.014), main pancreatic duct dilatation of more than 5 mm (P < 0.001), and jaundice (P < 0.001) were statistically significant variables. The developed statistical model has a c-index of 0.895. Implementation of the statistically significant variables in a predictive nomogram provided a reliable point system for estimating the presence of IPMN-associated invasive carcinoma.
CONCLUSIONS: NLR is an independent predictive marker for the presence of IPMN-associated invasive carcinoma. Further prospective studies are needed to assess the predictive ability of NLR and how it can be applied in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27631774     DOI: 10.1097/SLA.0000000000001988

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  45 in total

1.  The Prognostic Impact of the Lymphocyte-to-Monocyte Ratio in Resected Pancreatic Head Adenocarcinoma.

Authors:  Shunsuke Onoe; Atsuyuki Maeda; Yuichi Takayama; Yasuyuki Fukami; Takamasa Takahashi; Masahito Uji; Yuji Kaneoka
Journal:  Med Princ Pract       Date:  2019-05-20       Impact factor: 1.927

2.  Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Mohammad A Al Efishat; Marc A Attiyeh; Anne A Eaton; Mithat Gönen; Denise Prosser; Anna E Lokshin; Carlos Fernández-Del Castillo; Keith D Lillemoe; Cristina R Ferrone; Ilaria Pergolini; Mari Mino-Kenudson; Neda Rezaee; Marco Dal Molin; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Christopher L Wolfgang; Peter J Allen
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

Review 3.  Early detection of pancreatic cancer.

Authors:  Stephen P Pereira; Lucy Oldfield; Alexander Ney; Phil A Hart; Margaret G Keane; Stephen J Pandol; Debiao Li; William Greenhalf; Christie Y Jeon; Eugene J Koay; Christopher V Almario; Christopher Halloran; Anne Marie Lennon; Eithne Costello
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-02

Review 4.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

Review 5.  [Resection of main duct and mixed type IPMN ≥5 mm].

Authors:  G O Ceyhan; F Scheufele; H Friess
Journal:  Chirurg       Date:  2017-11       Impact factor: 0.955

6.  Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.

Authors:  Vinicius J Campos; Guilherme S Mazzini; José F Juchem; Richard R Gurski
Journal:  J Gastrointest Surg       Date:  2019-11-19       Impact factor: 3.452

7.  The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Fabio Bagante; Katiuscha Merath; Malcolm H Squires; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Olivier Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-01-19       Impact factor: 3.452

Review 8.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

9.  The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas.

Authors:  Hiromasa Yamamoto; Kei Namba; Haruchika Yamamoto; Tomohiro Toji; Junichi Soh; Kazuhiko Shien; Ken Suzawa; Takeshi Kurosaki; Shinji Otani; Mikio Okazaki; Seiichiro Sugimoto; Masaomi Yamane; Katsuhito Takahashi; Toshiyuki Kunisada; Takahiro Oto; Shinichi Toyooka
Journal:  Surg Today       Date:  2020-08-03       Impact factor: 2.549

10.  The Prognostic Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Resected Patients with Pancreatic Adenocarcinoma.

Authors:  Le-Ping Fang; Xiao-Yan Xu; Yu Ji; Pu-Wen Huang
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.